Emactuzumab(RG 7155) (i.v.; 0.1, 1, 10, 30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates’ peripheral blood[2].
RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1R+CD163+ macrophages in vivo[2].
| Animal Model: | cynomolgus monkeys Macaca fascicularis[2] |
| Dosage: | 0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys)
0, 30, and 100 mg/kg (male and female cynomolgus)
|
| Administration: | i.v., once (male cynomolgus monkeys)
i.v., once weekly, for 2 weeks(male and female cynomolgus)
|
| Result: | Increased CSF-1 concentration in serum.
Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.
|
